Demethyleneberberine ameliorates pulmonary fibrosis by inhibiting the NLRP3 inflammasome and the epithelial–mesenchymal transition
DMB ameliorates pulmonary fibrosis by inhibiting NLRP3 inflammasome activation and suppressing the EMT. Inhibition of NLRP3 appears to play a critical role in mediating the antifibrotic effects of DMB. These findings imply that DMB may represent a promising therapeutic candidate for clinical management of IPF.
Authors
- Yu-Ting Lin (ORCID: https://orcid.org/0000-0002-4821-9680)
- Chengshui Chen (ORCID: https://orcid.org/0000-0002-4341-0443)
- Liqin Zhou (ORCID: https://orcid.org/0000-0002-3802-1769)
- Zhiyi Tang (ORCID: https://orcid.org/0000-0001-7463-694X)
- Beibei Wang (ORCID: https://orcid.org/0000-0001-5887-4286)
- Xinyu Wu (ORCID: https://orcid.org/0000-0002-5293-5479)
- Xinye Wang (ORCID: https://orcid.org/0000-0003-2095-6117)
- Yuxi Lin (ORCID: https://orcid.org/0000-0001-9284-2659)
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1016/j.intimp.2025.115003
- Citations
- 1
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52